Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce Sanders

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
The Journal of Experimental Medicine|March 15, 2023
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanomaIrene L M Reijers, Disha Rao, Judith M Versluis, et al.
International Journal of Cancer|May 18, 2022
Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trialSimone N Koole, Philip C Schouten, Jan Hauke, et al.
BJU International|February 7, 2023
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomyFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
Cancer Discovery|June 27, 2022
Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen IndependenceSimon Linder, Marlous Hoogstraat, Suzan Stelloo, et al.
European Urology|July 20, 2020
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?<sup>†</sup>Bas W G van Rhijn, Laura S Mertens, Roman Mayr, et al.
Urologic Oncology|December 15, 2021
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patientsLaura S Mertens, Francesco Claps, Roman Mayr, et al.
Nature Genetics|July 22, 2020
Prostate cancer reactivates developmental epigenomic programs during metastatic progressionMark M Pomerantz, Xintao Qiu, Yanyun Zhu, et al.
BMC Medicine|July 4, 2015
Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosisMarcelo Sobral-Leite, Jelle Wesseling, Vincent T H B M Smit, et al.
Ebiomedicine|August 20, 2015
Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in CancerFrancisco J Candido Dos Reis, Stuart Lynn, H Raza Ali, et al.
The Journal of Pathology. Clinical Research|August 9, 2016
Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association ConsortiumWilliam J Howat, Fiona M Blows, Elena Provenzano, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
The Journal of Experimental Medicine|March 15, 2023
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanomaIrene L M Reijers, Disha Rao, Judith M Versluis, et al.
International Journal of Cancer|May 18, 2022
Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trialSimone N Koole, Philip C Schouten, Jan Hauke, et al.
BJU International|February 7, 2023
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomyFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
Cancer Discovery|June 27, 2022
Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen IndependenceSimon Linder, Marlous Hoogstraat, Suzan Stelloo, et al.
European Urology|July 20, 2020
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?<sup>†</sup>Bas W G van Rhijn, Laura S Mertens, Roman Mayr, et al.
Urologic Oncology|December 15, 2021
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patientsLaura S Mertens, Francesco Claps, Roman Mayr, et al.
Nature Genetics|July 22, 2020
Prostate cancer reactivates developmental epigenomic programs during metastatic progressionMark M Pomerantz, Xintao Qiu, Yanyun Zhu, et al.
BMC Medicine|July 4, 2015
Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosisMarcelo Sobral-Leite, Jelle Wesseling, Vincent T H B M Smit, et al.
Ebiomedicine|August 20, 2015
Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in CancerFrancisco J Candido Dos Reis, Stuart Lynn, H Raza Ali, et al.
The Journal of Pathology. Clinical Research|August 9, 2016
Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association ConsortiumWilliam J Howat, Fiona M Blows, Elena Provenzano, et al.
Pageof 9